Last reviewed · How we verify

Topical Chlorhexidine, 4%

VA Office of Research and Development · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Topical Chlorhexidine, 4% is a Small molecule drug developed by VA Office of Research and Development. It is currently FDA-approved.

Topical Chlorhexidine is a small molecule antiseptic used to reduce bacterial load on the ocular surface before cataract surgery. It has been studied in various clinical trials for conditions such as neonatal sepsis, omphalitis, and conjunctiva-related issues, among others.

At a glance

Generic nameTopical Chlorhexidine, 4%
SponsorVA Office of Research and Development
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical Chlorhexidine, 4%

What is Topical Chlorhexidine, 4%?

Topical Chlorhexidine, 4% is a Small molecule drug developed by VA Office of Research and Development.

Who makes Topical Chlorhexidine, 4%?

Topical Chlorhexidine, 4% is developed and marketed by VA Office of Research and Development (see full VA Office of Research and Development pipeline at /company/va-office-of-research-and-development).

What development phase is Topical Chlorhexidine, 4% in?

Topical Chlorhexidine, 4% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing